University of Washington
Robert J Hunter
1705 NE Pacific St
Dept of Comparative Medicine, HSB I-458
Seattle, WA 98195
http://www.uwtransgenics.org/
RRID: RRID:SCR_017863
Cell Culture
CRISPR
CRISPR Injection Services
CRISPR/Cas Project Design
Embryo Cryopreservation & Recovery Services
ES Cell Electroporation
ES Cell Injection
ES Cell Technology (Mouse)
Transgenics
1.) Guo R, Hua Y, Ren J, Bornfeldt KE, Nair S (2018 Jun 7). Cardiomyocyte-specific disruption of Cathepsin K protects against doxorubicin-induced cardiotoxicity. Cell death & disease, 9(6), 692. doi: 10.1038/s41419-018-0727-2. PMID: 29880809.
2.) Yamamoto K, Miki Y, Sato M, Taketomi Y, Nishito Y, Taya C, Muramatsu K, Ikeda K, Nakanishi H, Taguchi R, Kambe N, Kabashima K, Lambeau G, Gelb MH, Murakami M (2015 Oct 19). The role of group IIF-secreted phospholipase A2 in epidermal homeostasis and hyperplasia. The Journal of experimental medicine, 212(11), 1901-19. . PMID: 26438362.
3.) Chen J, Kaiyala KJ, Lam J, Agrawal N, Nguyen L, Ogimoto K, Spencer D, Morton GJ, Schwartz MW, Dichek HL (2015 Apr). In vivo structure-function studies of human hepatic lipase: the catalytic function rescues the lean phenotype of HL-deficient (hl-/-) mice. Physiological reports, 3(4), . . PMID: 25862097.
4.) Jhingran A, Kasahara S, Shepardson KM, Junecko BA, Heung LJ, Kumasaka DK, Knoblaugh SE, Lin X, Kazmierczak BI, Reinhart TA, Cramer RA, Hohl TM (2015 Jan). Compartment-specific and sequential role of MyD88 and CARD9 in chemokine induction and innate defense during respiratory fungal infection. PLoS pathogens, 11(1), e1004589. doi: 10.1371/journal.ppat.1004589. PMID: 25621893.
5.) Miki Y, Yamamoto K, Taketomi Y, Sato H, Shimo K, Kobayashi T, Ishikawa Y, Ishii T, Nakanishi H, Ikeda K, Taguchi R, Kabashima K, Arita M, Arai H, Lambeau G, Bollinger JM, Hara S, Gelb MH, Murakami M (2013 Jun 3). Lymphoid tissue phospholipase A2 group IID resolves contact hypersensitivity by driving antiinflammatory lipid mediators. The Journal of experimental medicine, 210(6), 1217-34. . PMID: 23690440.
The Transgenic Resources Program (TRP) is a core facility that creates transgenic and gene-targeted mice using pronuclear microinjection, targeted ES cell microinjection, and CRISPR-Cas9 gene editing. The TRP also offers mouse rederivation services to create specific pathogen free mice or to revive cryopreserved mouse lines. Additionally, embryo and sperm cryopreservation services are available to provide long-term storage of valuable mouse strains or stocks. Our facility is available to all University of Washington investigators and outside institutions.
